Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board

Executive Summary

Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China. 
Advertisement

Related Content

Glenmark, Yuhan Partner for Ryaltris, Eyes On US Trajectory
Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron
Takeda's Weber: ‘Everything Relies On Our Ability To Deliver Innovative Medicines’
Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis
Esperion Expects Preferred Formulary Placement For Oral Cholesterol Drug Bempedoic Acid
Roche Primes New Push Via Cipla For Avastin, Actemra In India
Cipla Cuts Down In-House Biosimilars Plans
Teva JV Allows Takeda To Offload Mature Japan Portfolio

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124451

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel